Please login to the form below

Not currently logged in

Portland Health wins Mundipharma account

Handling communications for the pain, oncology and asthma specialist

Portland Health, the recently launched healthcare arm of Portland Communications, has been appointed by Mundipharma International to handle its corporate communications.

The Cambridge, UK-based pharmaceutical company is structured as a network of independent associated companies, consisting of privately owned businesses and joint ventures. Together they have a focus on therapy areas including pain, oncology, rheumatoid arthritis and respiratory.

High on the Portland Health's agenda will be to raise the profile of the recently launched asthma drug Flutiform (fluticasone/formoterol).

In addition, the comms agency will also be tasked with driving more general awareness of Mundipharma, as it looks to expand across Europe, in terms of employees, potential clients and partnerships.

"Mundipharma's way of doing business is groundbreaking in today's market,” explained Louise Fish, the recently appointed head of Portland Health.

"We're excited to be part of their journey and look forward to helping them to build on the success they have already achieved."

Fish will report to Georg Toufar, chief marketing officer and board director at Mundipharma, who said: "Mundipharma International is a success story worth telling.

"We are bringing new treatments to the European market to benefit patients and our business model means we achieve value for payers at the same time.

"We're delighted to be working with Portland to tell this story to the best and brightest people and businesses in the pharma industry throughout Europe."

17th April 2013

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge